

Roser Velasco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8710348/publications.pdf>

Version: 2024-02-01

56
papers

1,749
citations

279798

23
h-index

276875

41
g-index

59
all docs

59
docs citations

59
times ranked

1966
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	4.1	179
2	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	1.2	136
3	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	1.9	116
4	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 178-189.	4.4	92
5	Taxane-Induced Peripheral Neurotoxicity. <i>Toxics</i> , 2015, 3, 152-169.	3.7	87
6	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	4.1	86
7	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3116-3122.	1.2	69
8	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	3.1	67
9	Encephalitis Induced by Immune Checkpoint Inhibitors. <i>JAMA Neurology</i> , 2021, 78, 864.	9.0	61
10	Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 17-25.	3.1	57
11	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	1.9	43
12	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	3.1	42
13	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	2.3	37
14	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CLIPerINomS study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	3.1	36
15	Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 815-825.	1.2	36
16	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , 2013, 49, 2910-2918.	2.8	35
17	Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. <i>Neuro-Oncology</i> , 2016, 18, 707-715.	1.2	35
18	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	3.1	34

#	ARTICLE	IF	CITATIONS
19	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	3.1	32
20	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: a post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , 2013, 20, 788-794.	3.3	30
21	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S52-S62.	3.1	30
22	Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 545-554.	2.9	25
23	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	2.2	23
24	Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 166-174.	3.1	21
25	Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1793-1801.	2.5	20
26	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	3.1	20
27	An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. <i>Neuro-Oncology</i> , 2016, 18, 950-961.	1.2	17
28	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 1991-1995.	2.2	17
29	Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 282-289.	2.1	16
30	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.1	16
31	Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. <i>Neural Regeneration Research</i> , 2018, 13, 775.	3.0	16
32	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	1.9	16
33	Refractory status epilepticus due to SMART syndrome. <i>Epilepsy and Behavior</i> , 2015, 49, 189-192.	1.7	15
34	Oxaliplatin Neurotoxicity. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 303-312.	0.5	13
35	Late effects of cancer treatment: consequences for long-term brain cancer survivors. <i>Neuro-Oncology Practice</i> , 2021, 8, 18-30.	1.6	12
36	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	3.1	11

#	ARTICLE	IF	CITATIONS
37	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. Expert Review of Neurotherapeutics, 2022, 22, 65-76.	2.8	11
38	Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers, 2021, 13, 6125.	3.7	11
39	Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2016, 21, 134-141.	3.1	10
40	Can leptomeningeal myelomatosis be predicted in patients with IgD multiple myeloma?. Journal of Clinical Neuroscience, 2010, 17, 1071-1072.	1.5	9
41	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. Anti-Cancer Drugs, 2021, 32, 88-94.	1.4	8
42	Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. Journal of Personalized Medicine, 2021, 11, 669.	2.5	8
43	TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients. Cells, 2022, 11, 209.	4.1	6
44	Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. Clinical and Translational Oncology, 2021, 23, 1761-1768.	2.4	3
45	Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. EJHaem, 2021, 2, 112-114.	1.0	1
46	P17.02- Diagnostic delay and treatment options of Primary Central Nervous System Lymphoma in the last decade: preliminary results of first 50 patients from two Catalan institutions. Neuro-Oncology, 2016, 18, iv77-iv77.	1.2	0
47	P16.01- Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial.. Neuro-Oncology, 2016, 18, iv76-iv76.	1.2	0
48	P14.04- Retreatment with oxaliplatin in CRC is safe in terms of neurotoxicity. Neuro-Oncology, 2016, 18, iv73-iv74.	1.2	0
49	Initial management of primary central nervous system lymphoma in Spain in the last decade. The experience of the GELTAMO and Spanish neuro-oncology groups. Hematological Oncology, 2017, 35, 354-355.	1.7	0
50	P05.21 T1-flair to T1-gadolinium MRI ratio as a predictive value of treatment response in non-small-cell lung cancer (NSCLC) patients affected by multiple brain metastases. Neuro-Oncology, 2018, 20, iii307-iii307.	1.2	0
51	Corrigendum. Neuro-Oncology, 2018, , .	1.2	0
52	P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors. Neuro-Oncology, 2019, 21, iii41-iii41.	1.2	0
53	Paraneoplastic Encephalomyelitis With Glutamic Acid Decarboxylase Antibodies Presenting as Longitudinal Pyramidal Tract Hyperintensity. JAMA Neurology, 2020, 77, 899.	9.0	0
54	Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial.. Journal of Clinical Oncology, 2015, 33, e20713-e20713.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Breast-GPA and type of treatment predictors of survival in brain metastasis patients.. Journal of Clinical Oncology, 2016, 34, e13530-e13530.	1.6	0
56	Ocular involvement in patients with primary centralâ€nervousâ€system lymphoma: Analysis of a multicentre study in Spain. British Journal of Haematology, 2022, , .	2.5	0